Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18957070 | 1.00 | MTNR1A (0.35) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL18957249 | 0.98 | MTNR1A (0.35) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL18957251 | 0.98 | MTNR1A (0.35) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL17337487 | 0.97 | MAPT (0.35) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL17337484 | 0.97 | MAPT (0.35) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL18957196 | 0.96 | MTNR1A (0.36) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL18957194 | 0.96 | MTNR1A (0.36) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL23130054 | 0.91 | MTNR1A (0.36) | MTNR1AMTNR1BMAPTATM | |
| SCHEMBL17347753 | 0.91 | MTNR1A (0.36) | MTNR1AMTNR1BMAPTATM | |
| SCHEMBL17337389 | 0.89 | ATM (0.32) | MTNR1AMTNR1BMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | MTNR1A 3641/4885MTNR1B 3337/4885MAPT 4167/4885 |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MTNR1A 3641/4885MTNR1B 3337/4885MAPT 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.